Profile Image

Dr Kelly Kiejda

Research Fellow

School of Biomedical Sciences and Pharmacy (Medical Genetics)

Cancer crusader

Dr Kelly Avery-Kiejda hopes to improve diagnosis and treatment for breast cancer sufferers by identifying new biomarkers for the disease.

Kelly Avery-Kiejda in the laboratory 

A protein known as 'the guardian of the genome' has been a source of scientific fascination to molecular biologist Dr Kelly Avery-Kiejda for the past seven years. The P53 protein is so named for its ability to prevent the propagation of mutations that can lead to cancer.

P53 is a tumour suppressor, which can put the brakes on cancer by inhibiting the division of cells with DNA damage. But the protein is deactivated in many types of cancers, neutralising this powerful protection against the disease. Avery-Kiejda's research is focused on gaining a better understanding of the function of the protein and the factors that influence its activation.

Avery-Kiejda's first postdoctoral project in 2005 involved the investigation of isoforms (variants) of P53 and their links to chemotherapy resistance in melanoma. She is now applying that expertise to breast cancer research, looking specifically at the role the protein plays in the progression of advanced cancer, with the aim of developing a better method of diagnosing a cancer's potential to develop metastases.

"P53 isoforms were only discovered in 2005 and there is very little known about their role in breast cancer. We are one of the few groups studying that and, to my knowledge, unique in our emphasis on their role in promoting metastatic disease," Avery-Kiejda points out. "Breast cancer, or any cancer, essentially becomes incurable once a secondary cancer develops, so if we can identify markers that will indicate at an early stage whether a patient is more likely to develop a metastasis, then we can treat that patient differently from the outset."

In a related line of research, Avery-Kiejda is pursuing a project that could expand treatment options for women diagnosed with triple-negative forms of breast cancer, which are resistant to most conventional forms of hormone therapy. Since 2009, she has been a key researcher on a multi-site project funded by the National Breast Cancer Foundation (NBCF) analysing the expression of microRNAs. These small molecules are known to play a role in some cancers and can be used as a prognostic tool. In a novel finding, her team has identified a subset of 27 microRNAs that appear to be irregular in breast cancer patients who have developed lymph node metastases.

"This is a critical and very exciting finding because it means we may be able to use this information either to develop a treatment target or to diagnose secondary cancers earlier," Avery-Kiejda explains. "We have been looking at this specifically in triple-negative breast cancers but it may be applicable to others as well."

Avery-Kiejda's research has attracted the support of key cancer organisations, including Cure Cancer Australia, Cancer Australia and the Melanoma Institute Australia. Her affiliation with the University of Newcastle and the Hunter Medical Research Institute (HMRI) has opened collaborations with influential researchers such as the Australia and New Zealand Breast Cancer Trials Group research director Professor John Forbes and internationally recognised cancer geneticist Professor Rodney Scott.

"Everyone, myself included, knows someone who has been affected by cancer," she notes. "It has always been my dream to do something that will make a difference to patients by contributing to more effective treatment strategies."

Visit the Centre for Cancer

Visit the HMRI website

Kelly Avery-Kiejda in the laboratory

Cancer crusader

Dr Kelly Avery-Kiejda hopes to improve diagnosis and treatment for breast cancer sufferers by identifying new biomarkers for the disease.

Read more

Career Summary

Biography

Research Expertise
Kelly Avery-Kiejda's research interests are: - understanding the molecular mechanisms of cancer development and the resistance of cancer to treatment - understanding how p53 function becomes de-regulated in cancer, in particular, melanoma and breast cancer - the role of miRNAs in advanced breast cancer

Teaching Expertise
Dr Avery-Kiejda is a full-time research academic. Currently, Dr Avery-Kiejda is the mentor of an early career postdoctoral fellow and the supervisor of 4 PhD candidates. - She has been the primary and co-supervisor of 2 Honours students (received 1st class Honours). - She was the sole supervisor of 3 undergraduate students for their 3rd year projects in the Biotechnology and Biomedical Science degree - She was a demonstrator for the subject Molecular Genetics (2000).

Administrative Expertise
Journal Peer Review - Reviewer for: Neoplasia, Clinical Cancer Research, Molecular Cancer Therapeutics, International Journal of Cancer, Clinical & Experimental Metastasis, BMC Cancer, Breast Cancer Research, Cell & Tissue Research, British Journal of Cancer Grant Peer review - Member of the Cancer Australia Grant Review Committee (2013) - External assessor for NHMRC project grant funding rounds (2011, 2012, 2014) - Assessor for the Hunter Translation Cancer Research Unit pilot project grant rounds (2012)



Qualifications

  • PhD (Medicine), University of Sydney
  • Bachelor of Science (Biotechnology)(Honours), University of Newcastle

Keywords

  • breast cancer
  • gene expression
  • miRNA
  • p53

Fields of Research

CodeDescriptionPercentage
111201Cancer Cell Biology30
111203Cancer Genetics30
111299Oncology and Carcinogenesis not elsewhere classified40

Professional Experience

UON Appointment

DatesTitleOrganisation / Department
1/07/2015 - 1/09/2015Research FellowUniversity of Newcastle
School of Biomedical Sciences and Pharmacy
Australia

Academic appointment

DatesTitleOrganisation / Department
1/01/2013 - 31/12/2013Membership - 2013 ASMR Gala Dinner Organising Committee, 6th June, Merewether Surfhouse, Newcastle 2013 ASMR Gala Dinner Organising Committee, 6th June, Merewether Surfhouse, Newcastle
Australia
1/01/2013 - Membership - Australian Society for Biochemistry and Molecular BiologyAustralian Society for Biochemistry and Molecular Biology
Australia
1/03/2012 - 1/03/2013Hunter Translational Cancer Research Unit FellowUniversity of Newcastle
Australia
1/01/2012 - 31/12/2012Membership - Organising committee for the 2012 ASMR Cocktail Party, Newcastle, NSW, Australia. Held on the 21st September,cOrganising committee for the 2012 ASMR Cocktail Party, Newcastle, NSW, Australia. Held on the 21st September,
Australia
1/01/2012 - 31/12/2012Membership - Organising committee for the 2012 5th Annual Hunter Cancer Research Symposium, Newcastle, NSW, Australia. Held on 2nd November 2012. Organising committee for the 2012 5th Annual Hunter Cancer Research Symposium, Newcastle, NSW, Australia. Held on 2nd November 2012.
Australia
1/01/2012 - 31/12/2013Membership - Organising committee for the 2013 Translational Cancer Research Conference, Newcastle, Australia Organising committee for the 2013 Translational Cancer Research Conference, Newcastle, Australia
Australia
1/01/2012 - Membership - Research Enabling Committee of the Hunter Translational Cancer Research Unit Research Enabling Committee of the Hunter Translational Cancer Research Unit
Australia
1/01/2012 - 31/12/2012Conference Chair - Session chair at the 2012 5th Annual Hunter Cancer Research Symposium, Newcastle, NSW, Australia. Held on 2nd November 2012.Session chair at the 2012 5th Annual Hunter Cancer Research Symposium, Newcastle, NSW, Australia. Held on 2nd November 2012.
Australia
1/01/2012 - Membership - Institutional Biosafety CommitteeInstitutional Biosafety Committee
Australia
1/01/2012 - Membership - The NHMRC Postdoctoral Reference GroupThe NHMRC Postdoctoral Reference Group
Australia
1/01/2012 - 31/12/2012Membership - 2012 ASMR Gala Dinner Organising Committee, 7th June, Customs House, Newcastle 2012 ASMR Gala Dinner Organising Committee, 7th June, Customs House, Newcastle
Australia
1/01/2011 - Membership - Hunter Medical Research Institute Disaster Sub-Plan CommitteeHunter Medical Research Institute Disaster Sub-Plan Committee
Australia
1/01/2011 - Membership - The Australian Microarray and Associated Technologies AssociationThe Australian Microarray and Associated Technologies Association
Australia
1/01/2011 - 31/12/2011Conference Chair - Session chair at the 2011 4th Annual Hunter Medical Research Institute Cancer Research Program Symposium, Newcastle, NSW, Australia. Held on 4th November, 2011.Session chair at the 2011 4th Annual Hunter Medical Research Institute Cancer Research Program Symposium, Newcastle, NSW, Australia. Held on 4th November, 2011.
Australia
1/01/2011 - 31/12/2011Membership - Organising committee for the 4th Annual Hunter Medical Research Institute Cancer Research Program Symposium, Newcastle, NSW, AustraliaOrganising committee for the 4th Annual Hunter Medical Research Institute Cancer Research Program Symposium, Newcastle, NSW, Australia
Australia
1/08/2005 - 1/09/2009Postdoctoral Research FellowUniversity of Newcastle
School of Biomedical Sciences and Pharmacy
Australia
1/08/2005 - 1/09/2009Cameron Melanoma Research FellowCalvary Mater Newcastle Hospital
Australia
1/01/2001 - 31/12/2005Membership - Australian Society for Medical Research (ASMR)Australian Society for Medical Research (ASMR)
Australia
1/02/2000 - 1/06/2000Laboratory DemonstratorUniversity of Newcastle
School of Environmental and Life Sciences
Australia

Awards

Recipient

YearAward
2001Australian Postgraduate Award
University of Sydney
2001Millennium Foundation Stipend Enhancement Grant
Unknown

Recognition

YearAward
2012Emerging research leaders program
University of Newcastle
1999Deans Commendation List
University of Newcastle
1998Most Outstanding Performance in the subject Cell and Molecular Biology
University of Newcastle

Research Award

YearAward
2010HMRI PULSE Education Prize
Unknown
2006HMRI Translational Cancer Research Conference Early Career Researcher Poster Award
Hunter Medical Research Institute

Invitations

Speaker

YearTitle / Rationale
2012MicroRNA expression profiling in triple-negative breast cancer.
Organisation: The 9th International RNAi, MicroRNAs and Single Cell Biology Meeting, 1st-2nd May, 2012, Boston
2012Small p53 Isoforms- BIG Implications for Prognosis and Treatment Response in Cancer.
Organisation: 22nd Annual Queenstown Molecular Biology Meeting: Cancer Biology Satellite. 26-27th August, 2012, Queenstown
2011MicroRNA expression profiling in triple-negative breast cancer
Organisation: Pharmacy Australia Centre of Excellence (PACE), School of Pharmacy, The University of Queensland Description: Invited to present my research at the Seminar series for Pharmacy Australia Centre of Excellence (PACE), School of Pharmacy, The University of Queensland, Woolloongabba, QLD. 28th April, 2011.
2008Small isoforms of p53: Do they contribute to melanoma chemoresistance?
Organisation: Research Seminar Series for the Melanoma Foundation, 15th August 2008., Sydney, NSW
2006The role of p53 variants in human melanoma
Organisation: The Melanoma and Skin Cancer Research Institute (MASCRI) Seminar Series, 20th October 2006, Sydne y, NSW
Edit

Publications

For publications that are currently unpublished or in-press, details are shown in italics.


Journal article (25 outputs)

YearCitationAltmetricsLink
2015Stirzaker C, Zotenko E, Song JZ, Qu W, Nair SS, Locke WJ, et al., 'Methylome sequencing in triple-negative breast cancer reveals distinct methylation clusters with prognostic value.', Nat Commun, 6 5899 (2015)
DOI10.1038/ncomms6899Author URL
Co-authorsJohn Forbes, Rodney Scott
2015Dun MD, Chalkley RJ, Faulkner S, Keene S, Avery-Kiejda K, Scott RJ, et al., 'Proteotranscriptomic Profiling of 231-BR Breast Cancer Cells: Identification of Potential Biomarkers and Therapeutic Targets for Brain Metastasis.', Mol Cell Proteomics, (2015)
DOI10.1074/mcp.M114.046110Author URL
Co-authorsMurray Cairns, Hubert Hondermarck, Matt Dun
2014Avery-Kiejda KA, Braye SG, Forbes JF, Scott RJ, 'The expression of Dicer and Drosha in matched normal tissues, tumours and lymph node metastases in triple negative breast cancer', BMC CANCER, 14 (2014) [C1]
DOI10.1186/1471-2407-14-253Author URL
CitationsScopus - 4Web of Science - 4
Co-authorsJohn Forbes, Rodney Scott
2014Wong-Brown MW, Avery-Kiejda KA, Bowden NA, Scott RJ, 'Low prevalence of germline PALB2 mutations in Australian triple-negative breast cancer', International Journal of Cancer, 134 301-305 (2014) [C1]

Triple-negative breast cancer (TNBC) is a tumour classification that is defined by oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 receptor negativity. TNBCs share a similar gene expression profile to BRCA-mutated tumours, have been shown to carry a high proportion of BRCA mutations and have a more adverse prognosis compared to other types of breast tumours. PALB2 has been shown to be a moderate-penetrance breast cancer susceptibility gene and is involved in the same DNA damage repair pathway as BRCA1 and BRCA2; this raises the possibility that germline PALB2 mutations may be involved in the pathogenesis of TNBCs. In our study, we sequenced the coding regions of PALB2 (including intron/exon boundaries) in genomic DNA from 347 patients diagnosed with TNBC to determine the prevalence of deleterious mutations in this population. Two novel truncating mutations (c.758dup and c.2390del) and one previously detected truncating mutation (c.3113+5G>C) were found. In addition, five variants predicted to be protein-affecting were also identified. Our study shows that the prevalence of PALB2 germline mutations in individuals with TNBC is ~1%, similar to the prevalence of PALB2 germline mutation of 1% in familial non-BRCA1/2 breast cancer cohorts. © 2013 UICC.

DOI10.1002/ijc.28361
CitationsScopus - 1
Co-authorsNikola Bowden, Michelle Wong-Brown, Rodney Scott
2014Avery-Kiejda KA, Braye SG, Mathe A, Forbes JF, Scott RJ, 'Decreased expression of key tumour suppressor microRNAs is associated with lymph node metastases in triple negative breast cancer', BMC Cancer, 14 (2014) [C1]

Background: Breast cancer is the most common malignancy that develops in women, responsible for the highest cancer-associated death rates. Triple negative breast cancers represent an important subtype that have an aggressive clinical phenotype, are associated with a higher likelihood of metastasis and are not responsive to current targeted therapies. miRNAs have emerged as an attractive candidate for molecular biomarkers and treatment targets in breast cancer, but their role in the progression of triple negative breast cancer remains largely unexplored.Methods: This study has investigated miRNA expression profiles in 31 primary triple negative breast cancer cases and in 13 matched lymph node metastases compared with 23 matched normal breast tissues to determine miRNAs associated with the initiation of this disease subtype and those associated with its metastasis.Results: 71 miRNAs were differentially expressed in triple negative breast cancer, the majority of which have previously been associated with breast cancer, including members of the miR-200 family and the miR-17-92 oncogenic cluster, suggesting that the majority of miRNAs involved in the initiation of triple negative breast cancer are not subtype specific. However, the repertoire of miRNAs expressed in lymph node negative and lymph node positive triple negative breast cancers were largely distinct from one another. In particular, miRNA profiles associated with lymph node negative disease tended to be up-regulated, while those associated with lymph node positive disease were down-regulated and largely overlapped with the profiles of their matched lymph node metastases. From this, 27 miRNAs were identified that are associated with metastatic capability in the triple negative breast cancer subtype.Conclusions: These results provide novel insight into the repertoire of miRNAs that contribute to the initiation of and progression to lymph node metastasis in triple negative breast cancer and have important implications for the treatment of this breast cancer subtype. © 2014 Avery-Kiejda et al.; licensee BioMed Central Ltd.

DOI10.1186/1471-2407-14-51
CitationsScopus - 6Web of Science - 7
Co-authorsRodney Scott, John Forbes
2014Avery-Kiejda KA, Braye SG, Forbes JF, Scott RJ, 'The expression of Dicer and Drosha in matched normal tissues, tumours and lymph node metastases in triple negative breast cancer.', BMC Cancer, 14 253 (2014)
DOI10.1186/1471-2407-14-253Author URL
CitationsScopus - 3Web of Science - 3
Co-authorsRodney Scott, John Forbes
2014Avery-Kiejda KA, Morten B, Wong-Brown MW, Mathe A, Scott RJ, 'The relative mRNA expression of p53 isoforms in breast cancer is associated with clinical features and outcome.', Carcinogenesis, 35 586-596 (2014) [C1]
DOI10.1093/carcin/bgt411Author URL
CitationsScopus - 2Web of Science - 2
Co-authorsRodney Scott, Michelle Wong-Brown
2013Bolton KA, Ross JP, Grice DM, Bowden NA, Holliday EG, Avery-Kiejda KA, Scott RJ, 'STaRRRT: a table of short tandem repeats in regulatory regions of the human genome', BMC GENOMICS, 14 (2013) [C1]
DOI10.1186/1471-2164-14-795Author URL
CitationsScopus - 4Web of Science - 5
Co-authorsRodney Scott, Nikola Bowden, Liz Holliday
2013Bowden NA, Ashton KA, Vilain RE, Avery-Kiejda KA, Davey RJ, Murray HC, et al., 'Regulators of Global Genome Repair Do Not Respond to DNA Damaging Therapy but Correlate with Survival in Melanoma', PLOS ONE, 8 (2013) [C1]
DOI10.1371/journal.pone.0070424Author URL
CitationsScopus - 1Web of Science - 1
Co-authorsXu Zhang, Nikola Bowden, Rodney Scott, Katie Ashton
2011Kiejda KA, Bowden NA, Croft AJ, Scurr LL, Kairupan CF, Ashton KA, et al., 'P53 in human melanoma fails to regulate target genes associated with apoptosis and the cell cycle and may contribute to proliferation', BMC Cancer, 11 203-219 (2011) [C1]
DOI10.1186/1471-2407-11-203
CitationsScopus - 28Web of Science - 21
Co-authorsKatie Ashton, Bente Talseth-Palmer, Rodney Scott, Nikola Bowden, Xu Zhang
2011Kiejda KA, Wong-Brown M, Scott R, 'Genetic markers in breast cancer - How far have we come from BRCA1?', Asia-Pacific Journal of Molecular Medicine, 1 1-15 (2011) [C1]
Co-authorsRodney Scott, Michelle Wong-Brown
2011Wong-Brown M, Nordfors C, Mossman D, Pecenpetelovska G, Kiejda KA, Talseth-Palmer B, et al., 'BRIP1, PALB2, and RAD51C mutation analysis reveals their relative importance as genetic susceptibility factors for breast cancer', Breast Cancer Research and Treatment, 127 853-859 (2011) [C1]
DOI10.1007/s10549-011-1443-0
CitationsScopus - 39Web of Science - 37
Co-authorsMichelle Wong-Brown, Nikola Bowden, Rodney Scott, Bente Talseth-Palmer
2010Bowden NA, Ashton KA, Kiejda KA, Zhang XD, Hersey P, Scott R, 'Nucleotide excision repair gene expression after cisplatin treatment in melanoma', Cancer Research, 70 7918-7926 (2010) [C1]
CitationsScopus - 8Web of Science - 7
Co-authorsKatie Ashton, Rodney Scott, Nikola Bowden, Xu Zhang
2009Jiang CC, Mao ZG, Kiejda KA, Hersey P, Zhang XD, 'Glucose-regulated protein 78 antagonizes cisplatin and adriamycin in human melanoma cells', Carcinogenesis, 30 197-204 (2009) [C1]
DOI10.1093/carcin/bgn220
CitationsScopus - 43Web of Science - 41
Co-authorsXu Zhang
2008Kiejda KA, Zhang XD, Adams LJ, Scott R, Vojtesek B, Lane DP, Hersey P, 'Small molecular weight variants of p53 are expressed in human melanoma cells and are induced by the DNA-damaging agent cisplatin', Clinical Cancer Research, 14 1659-1668 (2008) [C1]
DOI10.1158/1078-0432.ccr-07-1422
CitationsScopus - 49Web of Science - 44
Co-authorsRodney Scott, Xu Zhang
2008Chen LH, Jiang CC, Watts R, Thorne RF, Kiejda KA, Zhang XD, Hersey P, 'Inhibition of endoplasmic reticulum stress-induced apoptosis of melanoma cells by the ARC protein', Cancer Research, 68 834-842 (2008) [C1]
DOI10.1158/0008-5472.can-07-5056
CitationsScopus - 27Web of Science - 24
Co-authorsXu Zhang, Rick Thorne
2008Jiang CC, Lucas K, Kiejda KA, Wade M, Debock CE, Thorne RF, et al., 'Up-regulation of Mcl-1 is critical for survival of human melanoma cells upon endoplasmic reticulum stress', Cancer Research, 68 6708-6717 (2008) [C1]
DOI10.1158/0008-5472.can-08-0349
CitationsScopus - 73Web of Science - 69
Co-authorsXu Zhang, Rick Thorne
2008Zhu B-K, Wang P, Zhang XD, Jiang CC, Chen LH, Kiejda KA, et al., 'Activation of Jun N-terminal kinase is a mediator of vincristine-induced apoptosis of melanoma cells', Anti-Cancer Drugs, 19 189-200 (2008) [C1]
DOI10.1097/CAD.0b013e3282f3138a
CitationsScopus - 20Web of Science - 21
Co-authorsXu Zhang
2007Yu FW, Jiang CC, Kiejda KA, Gillespie S, Zhang XD, Hersey P, 'Apoptosis induction in human melanoma cells by inhibition of MEK is caspase-independent and mediated by the Bcl-2 family members PUMA, Bim, and Mcl-1', Clinical Cancer Research, 13 4934-4942 (2007) [C1]
DOI10.1158/1078-0432.CCR-07-0665
CitationsScopus - 96Web of Science - 106
Co-authorsXu Zhang
2007Mhaidat NM, Wang Y, Kiejda KA, Zhang XD, Hersey P, 'Docetaxel-induced apoptosis in melanoma cells is dependent on activation of caspase-2', Molecular Cancer Therapeutics, 6 752-761 (2007) [C1]
DOI10.1158/1535-7163.MCT-06-0564
CitationsScopus - 51Web of Science - 46
Co-authorsXu Zhang
2007Mhaidat NM, Zhang XD, Allen J, Kiejda KA, Scott R, Hersey P, 'Temozolomide induces senescence but not apoptosis in human melanoma cells', British Journal of Cancer, 97 1225-1233 (2007) [C1]
DOI10.1038/sj.bjc.6604017
CitationsScopus - 36Web of Science - 33
Co-authorsXu Zhang, Rodney Scott
2007Jiang CC, Li HC, Gillespie S, Kiejda KA, Mhaidat N, Yu FW, et al., 'Tunicamycin sensitizes human melanoma cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by up-regulation of TRAIL-R2 via the unfolded protein response', Cancer Research, 67 5880-5888 (2007) [C1]
DOI10.1158/0008-5472.CAN-07-0213
CitationsScopus - 61Web of Science - 61
Co-authorsXu Zhang, Rick Thorne
2007Jiang CC, Li HC, Gillespie S, Yu FW, Kiejda KA, Zhang XD, Hersey P, 'Inhibition of MEK sensitizes human melanoma cells to endoplasmic reticulum stress-induced apoptosis', Cancer Research, 67 9750-9761 (2007) [C1]
DOI10.1158/0008-5472.CAN-07-2047
CitationsScopus - 78Web of Science - 74
Co-authorsXu Zhang
2007Chen LH, Jiang CC, Kiejda KA, Wang YF, Thorne RF, Zhang XD, Hersey P, 'Thapsigargin sensitizes human melanoma cells to TRAIL-induced apoptosis by up-regulation of TRAIL-R2 through the unfolded protein response', Carcinogenesis, 28 2328-2336 (2007) [C1]
DOI10.1093/carcin/bgm173
CitationsScopus - 30Web of Science - 24
Co-authorsXu Zhang, Rick Thorne
2004Mote PA, Leary JA, Avery KA, Sandelin K, Chenevix-Trench G, Kirk JA, Clarke CL, 'Germ-line mutations in BRCA1 or BRCA2 in the normal breast are associated with altered expression of estrogen-responsive proteins and the predominance of progesterone receptor A. Genes Chromosomes Cancer 2004;39:236-48. (2004) [C1]
Show 22 more journal articles

Conference (73 outputs)

YearCitationAltmetricsLink
2014Morten B, Campbell HG, Brown MW, Mathe A, Braithwaite AW, Scott RJ, Kiejda KA, '¿40p53 regulation of estrogen responsiveness in breast cancer.', 16th International p53 Workshop Proceedings, Stockholm, Sweden (2014) [E3]
Co-authorsMichelle Wong-Brown, Rodney Scott
2014Morten B, Scott RJ, Avery-Kiejda KA, 'Comparison of the Quantigene 2.0 Assay for the detection of p53 isoform mRNA expression in FFPE tissues.', 16th International p53 Workshop Proceedings, Stockholm, Sweden (2014) [E3]
2014Morten B, Scott RJ, Kiejda KA, 'The role of ¿40p53 and p53 in Estrogen-Receptor-a signaling pathways in breast cancer.', 23rd Biennial Congress of the European Association for Cancer Research Proceedings Book, Munich, Germany (2014) [E3]
Co-authorsRodney Scott
2014Mathe A, Avery-Kiejda KA, Wong-Brown M, Forbes JF, Braye SG, Scott RJ, 'Eight microRNAs as biomarkers for metastatic spread in triple negative breast cancer.', 23rd Biennial Congress of the European Association for Cancer Research Proceedings Book, Munich, Germany (2014)
2014Morten B, Campbell HG, Wong-Brown MW, Mathe A, Braithwaite AW, Scott RJ, Avery-Kiejda KA, 'Delta-40P53 regulation of ERa-mediated signalling in breast cancer.', The 29th International Association for Breast Cancer Research Conference Proceedings, Manly, NSW, Australia (2014) [E3]
Co-authorsRodney Scott
2014Mathe A, Avery-Kiejda KA, Wong-Brown M, Forbes JF, Braye SG, Scott RJ, 'Can microRNAs impact cell migration in triple negative breast cancer?', The Australian Society for Medical Research (ASMR) Satellite Scientific Meeting Programme, Newcastle, NSW, Australia (2014) [E3]
Co-authorsRodney Scott, John Forbes
2014Morten B, Scott RJ, Avery-Kiejda KA, '¿40p53 and p53 mediate ER-a expression in breast cancer cells.', The Australian Society for Medical Research (ASMR) Satellite Scientific Meeting Programme, Newcastle, NSW, Australia (2014) [E3]
Co-authorsRodney Scott
2014Bolton KA, Ross JP, Grice DM, Bowden NA, Holliday EG, Avery-Kiejda KA, Scott RJ, 'Short tandem repeats are variable genetic elements that may have major consequences for multiple diseases.', The Australian Society for Medical Research (ASMR) Satellite Scientific Meeting Programme, Newcastle, NSW, Australia (2014)
Co-authorsLiz Holliday, Rodney Scott, Nikola Bowden
2014Avery-Kiejda KA, Morten B, Wong-Brown MW, Mathe A, Scott RJ, 'The relationship between p53 isoforms and prognosis in breast cancer.', The Australian Society for Medical Research (ASMR) Satellite Scientific Meeting Programme, Newcastle, NSW, Australia (2014) [E3]
Co-authorsMichelle Wong-Brown, Rodney Scott
2014Bolton KA, Ross JP, Grice DM, Bowden NA, Holliday EG, Kiejda KA, Scott RJ, 'Short tandem repeats are variable genetic elements that may have major consequences for multiple diseases.', The Australian Society for Medical Research (ASMR) Satellite Scientific Meeting Programme, Newcastle, NSW, Australia (2014) [E3]
Co-authorsRodney Scott, Liz Holliday, Nikola Bowden
2014Mathe A, Avery-Kiejda KA, Wong-Brown M, Morten B, Forbes JF, Braye SG, Scott RJ, 'IDENTIFICATION OF NOVEL TRANSCRIPTS SPECIFIC TO TRIPLE NEGATIVE BREAST CANCER THAT ARE ASSOCIATED WITH LYMPH NODE METASTASIS', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2014) [E3]
DOI10.1111/ajco.12335Author URL
Co-authorsJohn Forbes, Rodney Scott, Michelle Wong-Brown
2014Morten B, Scott RJ, Avery-Kiejda KA, 'Delta 40P53 CAN ALTER BREAST CANCER CELL GROWTH BY MEDIATING THE ESTROGEN RESPONSE', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2014) [E3]
Author URL
Co-authorsRodney Scott
2014Bolton KA, Holliday EG, McEvoy M, Attia J, Proietto A, Otton G, et al., 'A HIGHLY POLYMORPHIC AG REPEAT IN THE UPSTREAM REGULATORY REGION OF THE ESTROGEN-INDUCED GENE EIG121 IS A POTENTIAL MODIFIER OF ENDOMETRIAL CANCER RISK', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2014) [E3]
Author URL
Co-authorsNikola Bowden, John Attia, Liz Holliday, Rodney Scott
2014Mathe A, Avery-Kiejda KA, Wong-Brown M, Forbes JF, Braye SG, Scott RJ, 'Eight microRNAs as biomarkers for metastatic spread in triple negative breast cancer', EUROPEAN JOURNAL OF CANCER (2014) [E3]
Author URL
Co-authorsRodney Scott, Michelle Wong-Brown, John Forbes
2014Morten B, Scott RJ, Avery-Kiejda KA, 'The role of Delta-40p53 and p53 in Estrogen Receptor-alpha signalling pathways in breast cancer', EUROPEAN JOURNAL OF CANCER (2014) [E3]
Author URL
Co-authorsRodney Scott
2014Bolton KA, Holliday EG, Bowden NA, Avery-Kiejda KA, Scott RJ, 'A highly polymorphic AG repeat in the upstream regulatory region of the estrogen-induced gene EIG121 is a modifier of disease risk in endometrial cancer', EUROPEAN JOURNAL OF CANCER (2014) [E3]
Author URL
Co-authorsRodney Scott, Nikola Bowden, Liz Holliday
2014Bolton KA, Holliday EG, McEvoy M, Attia J, Proietto A, Otton G, et al., 'A highly polymorphic AG repeat in the upstream regulatory region of the estrogen gene EIG121 is a potential modifier of endometrial cancer risk.', Asia-Pacific Journal of Clinical Oncology, Newcastle, NSW, Australia (2014) [E3]
DOI10.1111/ajco.12335
Co-authorsJohn Attia, Nikola Bowden, Rodney Scott, Liz Holliday
2013Zotenko E, Stirzaker C, Song JZ, Qu W, Nair S, Avery-Kiejda KA, et al., 'Genome-wide DNA methylation analysis of archival formalin-fixed paraffin-embedded tissue (FFPET) using MDBCAP-Seq identifies novel epigenetic diagnostic biomarker loci in breast cancer.', 25th Lorne Cancer Conference Proceedings, Lorne, VIC, Australia (2013) [E3]
Co-authorsRodney Scott
2013Morten B, Mathe A, Scott RJ, Avery-Kiejda KA, 'mRNA expression analysis of p53 isoforms in breast cancer.', 25th Lorne Cancer Conference Proceedings, Lorne, VIC, Australia (2013) [E3]
Co-authorsRodney Scott
2013Avery-Kiejda KA, Mathe A, Braye SG, Forbes JF, Scott RJ, 'The expression of Dicer and Drosha in lymph node metastases of triple negative breast cancer.', 25th Lorne Cancer Conference Proceedings, Lorne, VIC, Australia (2013) [E3]
Co-authorsRodney Scott, John Forbes
2013Mathe A, Avery-Kiejda KA, Wong-Brown MW, Forbes JF, Braye SG, Scott RJ, 'Target gene identification of microRNAs associated with lymph node metastases in triple negative breast cancer.', 25th Lorne Cancer Conference Proceedings, Lorne, VIC, Australia (2013) [E3]
Co-authorsRodney Scott, Michelle Wong-Brown, John Forbes
2013Bolton KA, Ross J, Grice DM, Avery-Kiejda KA, Bowden NA, Holliday EG, Scott RJ, 'Role of Short Tandem Repeats in Disease and Evolutionary Mechanisms.', 34th Lorne Genome Conference Proceedings, Lorne, VIC, Australia (2013) [E3]
Co-authorsLiz Holliday, Rodney Scott, Nikola Bowden
2013Mathe A, Avery-Kiejda KA, Wong-Brown M, Forbes JF, Braye SG, Scott RJ, 'Integration of microRNA and gene expression profiling in triple negative breast cancer to identify possible biomarkers for metastases.', Breakthrough Breast Cancer TNBC Conference Proceedings, London, UK (2013) [E3]
Co-authorsRodney Scott, Michelle Wong-Brown, John Forbes
2013Wong-Brown M, Li S, Wilkins M, Avery-Kiejda KA, Bowden N, Scott R, 'Targeted resequencing of BRCA1 and BRCA2 in familial breast cancer.', Kathleen Cunningham Foundation Consortium for Research into Familial Aspects of Cancer 2013 Research and Practice Proceedings, Cairns, QLD, Australia. (2013) [E3]
Co-authorsMichelle Wong-Brown, Nikola Bowden, Rodney Scott
2013Wong-Brown M, Avery-Kiejda K, Bowden N, Scott R, 'Prevalence of BRCA1 and BRCA2 germline mutations in triple-negative breast cancer', Programme, Newcastle (2013) [E3]
CitationsWeb of Science - 1
Co-authorsRodney Scott, Michelle Wong-Brown, Nikola Bowden
2013Morten B, Scott RJ, Avery-Kiejda KA, 'Microarray analysis of differentially expressed genes in patients with high ¿40p53 expression.', Translational Cancer Research Conference Abstract booklet, Newcastle, Australia (2013) [E3]
Co-authorsRodney Scott
2013Bolton KA, Avery-Kiejda KA, Grice DM, Holliday EG, Bowden NA, Ross J, Scott RJ, 'STaRRRT: Our new resource for identifying candidates of genetic risk in breast and endometrial cancer.', Translational Cancer Research Conference Abstract booklet, Newcastle, Australia (2013) [E3]
Co-authorsNikola Bowden, Rodney Scott, Liz Holliday
2013Mathe A, Wong-Brown M, Forbes JF, Braye SG, Scott RJ, Avery-Kiejda KA, 'Identification of biomarkers for metastatic spread in triple negative breast cancer.', Translational Cancer Research Conference Abstract booklet, Newcastle, Australia (2013) [E3]
Co-authorsMichelle Wong-Brown, Rodney Scott, John Forbes
2012Bolton KA, Ross J, Grice DM, Kiejda KA, Bowden NA, Holliday EG, Scott R, 'Potential role of short tandem repeats in disease processes', Abstracts. 6th Australian Health & Medical Research Congress, Adelaide, SA (2012) [E3]
Co-authorsLiz Holliday, Rodney Scott, Nikola Bowden
2012Kiejda KA, Forbes JF, Braye SG, Scott R, 'Identification of miRNAs associated with lymph node metastasis in triple-negative breast cancer', Human Genome Meeting 2012: Genetics and Genomics in Personalised Medicine. Abstract Book, Sydney, NSW (2012) [E3]
Co-authorsJohn Forbes, Rodney Scott
2012Wong-Brown M, Li S, Wilkins M, Kiejda KA, Bowden NA, Scott R, 'Exploratory targeted resequencing of BRCA1 and BRCA2 in inherited breast cancer', Programme. kConFab Familial Aspects of Cancer: Research & Practice 2012, Kingscliff, NSW (2012) [E3]
Co-authorsRodney Scott, Nikola Bowden, Michelle Wong-Brown
2012Wong-Brown M, Li S, Wilkins M, Kiejda KA, Bowden NA, Scott R, 'Targeted resequencing of BRCA1 and BRCA2 in inherited breast cancer', Cancer Research, San Antonio, Texas (2012) [E3]
Co-authorsMichelle Wong-Brown, Nikola Bowden, Rodney Scott
2012Avery-Kiejda KA, Forbes JF, Braye SG, Scott RJ, 'Can Dicer explain decreased microRNA expression in lymph node metastases of triple negative breast cancer?', 14th International Biennial Congress of the Metastasis Research Society Delegate Handbook, Brisbane, QLD, Australia (2012)
2012Bowden NA, Ashton KA, Villain RE, Braye SG, Avery-Kiejda KA, Zhang XD, et al., 'Regulators of DNA repair do not respond to DNA damaging therapy but correlate with survival in melanoma.', 5th Annual Hunter Cancer Research Symposium Programme, Newcastle, NSW, Australia (2012)
2012Wong-Brown M, Li S, Wilkins M, Avery-Kiejda KA, Bowden NA, Scott RJ, 'Targeted resequencing of BRCA1 and BRCA2 in inherited breast cancer.', 5th Annual Hunter Cancer Research Symposium Programme, Newcastle, NSW, Australia (2012)
2012Avery-Kiejda KA, Forbes JF, Braye SG, Scott RJ, 'The expression of key tumour suppressor microRNAs is decreased in lymph-node positive triple-negative breast cancer.', 5th Annual Hunter Cancer Research Symposium Programme, Newcastle, NSW, Australia (2012)
2012Morten B, Scott RJ, Avery-Kiejda KA, 'p53 isoform expression is correlated with ER-alpha expression in breast cancer.', 5th Annual Hunter Cancer Research Symposium Programme, Newcastle, NSW, Australia (2012)
2012Bolton KA, Ross JP, Grice DM, Avery-Kiejda KA, Bowden NA, Holliday EG, Scott RJ, 'Short Tandem Repeats in Regulatory Regions of Human Genes: Where, What, How and Why??', 5th Annual Hunter Cancer Research Symposium Programme, Newcastle, NSW, Australia (2012)
2012Mathe A, Avery-Kiejda KA, Forbes JF, Braye SG, Scott RJ, 'The functional role of microRNAs associated with lymph node metastases in triple negative breast cancer.', 5th Annual Hunter Cancer Research Symposium Programme, Newcastle, NSW, Australia (2012)
2012Avery-Kiejda KA, Forbes JF, Braye SG, Scott RJ, 'MicroRNA expression profiling in triple-negative breast cancer.', RNAi, MicroRNAs and Single Cell Biology and Stem Cells 2012- Boston Metting Proceedings, Boston, USA (2012)
2012Avery-Kiejda KA, Morten B, Scott RJ, 'The expression of p53 isoforms in breast cancer.', The First Australian p53 Workshop Programme, Melbourne, VIC Australia (2012)
2012Morten B, Scott RJ, Avery-Kiejda KA, 'p53 isoforms and estrogen responsiveness in breast cancer.', The First Australian p53 Workshop Programme, Melbourne, VIC Australia (2012)
2011Bowden NA, Ashton KA, Kiejda KA, Zhang XD, Hersey P, Scott R, 'Downstream effects of reduction in nucleotide excision repair in response to cisplatin treatment in melanoma', Pigment Cell & Melanoma Research, Tampa, FL (2011) [E3]
DOI10.1111/j.1755-148X.2011.00909.x
Co-authorsXu Zhang, Nikola Bowden, Rodney Scott, Katie Ashton
2011Kiejda KA, Forbes JF, Hope TL, Braye SG, Scott R, 'Differential expression of miRNAs in triple-negative breast cancer', AMATA Conference Canberra 2011 Handbook, Canberra, ACT (2011) [E3]
Co-authorsRodney Scott, John Forbes
2011Kiejda KA, Forbes JF, Braye SG, Scott R, 'MicroRNA expression profiling in triple-negative breast cancer', Keystone Symposia on Mollecular and Cellular Biology: MicroRNAs and Non-coding RNAs and Cancer, Banff, AL (2011) [E3]
Co-authorsJohn Forbes, Rodney Scott
2011Avery-Kiejda KA, 'Cancer research at the Centre for Information-Based Medicine.', Hunter Medical Research Institute (HMRI) Cancer Research Program Symposium Proceedings, Newcastle, NSW, Australia (2011)
2010Croft AJ, Kiejda KA, Bowden NA, Zhang X, Scott R, Hersey P, 'Expression profiling on apoptosis-related genes in cisplatin-treated human melanoma cell lines', 22nd Lorne Cancer Conference: Abstracts and Delegate Information, Lorne, Vic. (2010) [E3]
Co-authorsNikola Bowden, Rodney Scott
2010Wong-Brown M, Bowden NA, Kiejda KA, Scott R, 'BRIP1 and PALB2 mutation detection in Hunter-New England familial breast cancer cohort', 27th HUGO-IABCR Congress 2010. Genomics, Biology and Breast Cancer Treatment. Programme & Abstract Book, Biopolis, Singapore (2010) [E3]
Co-authorsRodney Scott, Michelle Wong-Brown, Nikola Bowden
2010Bowden NA, Ashton KA, Kiejda KA, Zhang XD, Hersey P, Scott R, 'Altered nucleotide excision repair gene expression after cisplatin treatment in melanoma', AACR 101st Annual Meeting 2010. Abstracts, Washington, DC (2010) [E3]
DOI10.1158/0008-5472.CAN-10-0161
Co-authorsNikola Bowden, Rodney Scott, Katie Ashton, Xu Zhang
2010Ashton KA, Bowden NA, Kairupan CF, Kiejda KA, Zhang XD, Hersey P, Scott R, 'Base excision repair and gene expression profiling in malignant melanoma', Sydney Cancer Conference 2010. Profiling Risk, Personalising Treatment and Predicting Outcomes. Conference Program and Abstract Book, Sydney, NSW (2010) [E3]
Co-authorsKatie Ashton, Xu Zhang, Nikola Bowden, Rodney Scott
2010Kiejda KA, Forbes JF, Braye SG, Scott R, 'The relationship between p53 isofor and estrogen receptor-alpha expression in breast cancer', Sydney Cancer Conference 2010. Profiling Risk, Personalising Treatment and Predicting Outcomes. Conference Program and Abstract Book, Sydney, NSW (2010) [E3]
Co-authorsRodney Scott, John Forbes
2010Ashton KA, Bowden NA, Vilain RE, Kairupan CF, Kiejda KA, Zhang XD, et al., 'Genetic variation of the base excision repair gene, MUTYH, and melanoma development', Melanoma 2010 Congress. Oral and Poster Abstracts, Sydney, NSW (2010) [E3]
Co-authorsXu Zhang, Nikola Bowden, Katie Ashton
2010Bowden NA, Ashton KA, Kiejda KA, Vilain RE, Braye SG, Kairupan CF, et al., 'Nucleotide excision repair gene expression in melanoma', Melanoma 2010 Congress. Oral and Poster Abstracts, Sydney, NSW (2010) [E3]
DOI10.1158/0008-5472.CAN-10-0161
Co-authorsKatie Ashton, Xu Zhang, Nikola Bowden
2009Kiejda KA, Scurr LL, Wade MA, Jiang CC, Weir AJW, Bowden NA, et al., 'Cisplatin induces apoptosis independently of Noxa or PUMA in human melanoma cells', 21st Lorne Cancer Conference, Lorne, VIC (2009) [E3]
Co-authorsRodney Scott, Nikola Bowden, Xu Zhang
2009Zhang XD, Jiang CC, Kiejda KA, Hersey P, 'Up-regulation of Mcl-1 by the unfolded protein response is critical for survival of melanoma cells upon ER stress', 7th World Congress on Melanoma, 5th Congress of the European Association of Dermato-Oncology (EADO): Final Program, Vienna, Austria (2009) [E3]
Co-authorsXu Zhang
2008Bowden NA, Ashton KA, Kiejda KA, Zhang XD, Hersey P, Scott R, 'Altered nucleotide excision repair gene expression after cisplatin treatment in melanoma', Proceedings of the Australian Health and Medical Research Congress 2008, Brisbane, QLD (2008) [E3]
Co-authorsXu Zhang, Nikola Bowden, Rodney Scott, Katie Ashton
2008Zhang XD, Jiang CC, Avery-Kiejda KA, Lucas K, Wade M, Allen J, Hersey P, 'Up-regulation of Mcl-1 by the unfolded protein response is critical for survival of melanoma cells upon ER stress', PIGMENT CELL & MELANOMA RESEARCH (2008) [E3]
Author URL
Co-authorsXu Zhang
2008Kiejda KA, Zhang XD, Adams LJ, Scott R, Vojtesek B, Lane DP, Hersey P, 'The P53 splice variants, P53B and 40P53, are expressed in human melanoma cells and can differnetially regulate the transcription of P53 target genes in response to cisplatin', 20th Lorne Cancer Conference, Lorne, VIC (2008) [E3]
Co-authorsRodney Scott, Xu Zhang
2008Jiang CC, Wade MA, Kiejda KA, Wang Y, Zhang XD, Hersey P, 'Up-regulation of MCL-1 is critical for survival of human melanoma cells upon ER stress', 20th Lorne Cancer Conference, Lorne, VIC (2008) [E3]
Co-authorsXu Zhang
2008Zhang XD, Jiang CC, Wang YF, Kiejda KA, Hersey P, 'The MEK/ERK pathway potentiates adaptation of human melanoma to endoplasmic reticulum stress', 20th Lorne Cancer Conference, Lorne, VIC (2008) [E3]
Co-authorsXu Zhang
2007Jiang CC, Chen IH, Kiejda KA, Gillespie SK, Hersey P, Zhang XD, 'The unfolded protein response induced by tunicamycin or thapsigargin sensitizes human melanoma cells to trail-induced apoptosis by selective up-regulaton of trail-R2 on te cell surface', 19th Lorne Cancer Conference, Lorne, VIC (2007) [E3]
Co-authorsXu Zhang
2007Kiejda KA, Zhang XD, Hersey P, 'The P53 splice variant, P53B, is widely expressed in human melanoma', 19th Lorne Cancer Conference, Lorne, VIC (2007) [E3]
Co-authorsXu Zhang
2007Zhang XD, Jiang CC, Wang YF, Kiejda KA, Gillespie SK, Hersey P, 'Regulation of the BCL-2 family members BIM, PUMA and MCL-1 by MEK/ERK signaling plays a critical role in survival of melanoma cells', 19th Lorne Cancer Conference, Lorne, VIC (2007) [E3]
Co-authorsXu Zhang
2007Kiejda KA, Zhang XD, Adams LJ, Scott R, Vojtesek B, Lane DP, Hersey P, 'MEK/ERK-mediated regulation of the Bcl-2 family members Mcl-1, PUMA, and Bim contributes to survival of human melanoma cells', 4th Garvan Signalling Symposium. Conference Proceedings, Sydney, NSW (2007) [E3]
Co-authorsRodney Scott, Xu Zhang
2007Kiejda KA, Zhang XD, Adams LJ, Scott R, Vojtesek B, Lane DP, Hersey P, 'Small molecular weight variants of p53 are expressed in human melanoma cells and are induced by cisplatin', 4th Garvan Signalling Symposium. Conference Proceedings, Sydney, NSW (2007) [E3]
Co-authorsRodney Scott, Xu Zhang
2007Zhang XD, Jiang CC, Wang YF, Kiejda KA, Hersey P, 'The MEK-ERK pathway potentiates adaptation of melanoma to endoplasmic reticulum stress', 4th Garvan Signalling Symposium. Conference Proceedings, Sydney, NSW (2007) [E3]
Co-authorsXu Zhang
2007Jiang CC, Wang YF, Kiejda KA, Gillespie SK, Zhang XD, Hersey P, 'Regulation of the Bcl-2 family members Bim, PUMA and Mcl-1 by MEK/ERK signaling plays a critical role in survival of melanoma cells', AACR Meeting Abstracts Online (Abstracts of the 98th AACR Annual Meeting), Los Angeles (2007) [E3]
Co-authorsXu Zhang
2006Kiejda KA, Zhang XD, Hersey P, 'p53 variants in human melanoma', 13th Annual p53 Workshop. Program & Abstracts, New York (2006) [E3]
Co-authorsXu Zhang
2006Jiang CC, Wang YF, Kiejda KA, Zhang XD, Hersey P, 'CD133, A potential marker for cancer stem cells in melanoma', HMRI Conference on Translational Cancer Research. Molecular Mechanisms and Implications for Treatment, Newcastle, NSW (2006) [E3]
Co-authorsXu Zhang
2006Kiejda KA, Zhang XD, Hersey P, 'Expression of P53 variants in human melanoma', HMRI Conference on Translational Cancer Research. Molecular Mechanisms and Implications for Treatment, Newcastle, NSW (2006) [E3]
Co-authorsXu Zhang
2006Wang YF, Jiang CC, Kiejda KA, Zhang XD, Hersey P, 'Suppression of the BH3-only proteins BUM and PUMA by MEK/ERK signaling plays a crucial role in maintaining survival of melanoma cells', HMRI Conference on Translational Cancer Research. Molecular Mechanisms and Implications for Treatment, Newcastle, NSW (2006) [E3]
Co-authorsXu Zhang
2004Avery KA, Graham JD, Defazio A, Clarke CL, 'Co-localisation of the progesterone receptor with BRCA1 in human breast cancer cells' (2004) [E3]
2004Avery KA, Graham JD, Defazio A, Clarke CL, 'Endogenous levels of BRCA1 regulate progestin signalling' (2004) [E3]
Show 70 more conferences
Edit

Grants and Funding

Summary

Number of grants22
Total funding$1,513,025

Click on a grant title below to expand the full details for that specific grant.


20141 grants / $20,000

A new frontier in breast cancer: Can small molecules in the blood predict outcome?$20,000

Funding body: Hunter Medical Research Institute

Funding bodyHunter Medical Research Institute
Project TeamDoctor Kelly Kiejda, Doctor Jude Weidenhofer, Professor Rodney Scott
SchemeProject Grant
RoleLead
Funding Start2014
Funding Finish2014
GNoG1401454
Type Of FundingGrant - Aust Non Government
Category3AFG
UONY

20132 grants / $40,000

The function of the delta-40p53 isoform in breast cancer.$30,000

Funding body: Hunter Medical Research Institute

Funding bodyHunter Medical Research Institute
Project TeamDoctor Kelly Kiejda, Miss Brianna Morten, Professor Rodney Scott
SchemeProject Grant
RoleLead
Funding Start2013
Funding Finish2013
GNoG1300583
Type Of FundingContract - Aust Non Government
Category3AFC
UONY

miRNA regulation of growth, invasion and treatment response in triple negative breast cancer$10,000

Funding body: Hunter Medical Research Institute

Funding bodyHunter Medical Research Institute
Project TeamDoctor Kelly Kiejda, Miss Andrea Mathe
SchemeProject Grant
RoleLead
Funding Start2013
Funding Finish2013
GNoG1300728
Type Of FundingGrant - Aust Non Government
Category3AFG
UONY

20125 grants / $474,300

Small p53 isoforms, BIG implications for treatment response in breast cancer$90,000

Funding body: Hunter Medical Research Institute

Funding bodyHunter Medical Research Institute
Project TeamDoctor Kelly Kiejda, Professor Rodney Scott
SchemeProject Grant
RoleLead
Funding Start2012
Funding Finish2012
GNoG1200322
Type Of FundingContract - Aust Non Government
Category3AFC
UONY

p53 isoforms in breast cancer - MM Sawyer Estate Scholarship$75,000

Funding body: Hunter Medical Research Institute

Funding bodyHunter Medical Research Institute
Project TeamDoctor Kelly Kiejda, Professor Rodney Scott
SchemeMary Minto Sawyer Grant
RoleLead
Funding Start2012
Funding Finish2012
GNoG1200615
Type Of FundingGrant - Aust Non Government
Category3AFG
UONY

2011 Emerging Research Leaders Program$15,000

Funding body: University of Newcastle

Funding bodyUniversity of Newcastle
Project TeamDoctor Kelly Kiejda
SchemeEmerging Research Leaders Program
RoleLead
Funding Start2012
Funding Finish2012
GNoG1200817
Type Of FundingInternal
CategoryINTE
UONY

Ninth International NRAi, MicroRNAs & Single Cell Biology - 2012, Hilton Garden Inn, Waltham, Massachusetts, USA, 1 - 2 May 2012$2,000

Funding body: University of Newcastle - Faculty of Health and Medicine

Funding bodyUniversity of Newcastle - Faculty of Health and Medicine
Project TeamDoctor Kelly Kiejda
SchemeTravel Grant
RoleLead
Funding Start2012
Funding Finish2012
GNoG1200588
Type Of FundingInternal
CategoryINTE
UONY

20113 grants / $50,375

p53 isoforms, a prognostic indicator in breast cancer?$45,000

Funding body: Hunter Medical Research Institute

Funding bodyHunter Medical Research Institute
Project TeamDoctor Kelly Kiejda, Professor Rodney Scott, Professor John Forbes
SchemeBreast Cancer Project Grant
RoleLead
Funding Start2011
Funding Finish2011
GNoG1001006
Type Of FundingContract - Aust Non Government
Category3AFC
UONY

PULSE Education Prize$4,000

Funding body: Hunter Medical Research Institute

Funding bodyHunter Medical Research Institute
Project TeamDoctor Kelly Kiejda
SchemePULSE Education Prize
RoleLead
Funding Start2011
Funding Finish2011
GNoG1001021
Type Of FundingContract - Aust Non Government
Category3AFC
UONY

Annual meeting fo the Australasian Microarray & Associated Technologies Association (AMATA), Shine Dome in Canberra, 9 - 12 October 2011$1,375

Funding body: University of Newcastle - Faculty of Health and Medicine

Funding bodyUniversity of Newcastle - Faculty of Health and Medicine
Project TeamDoctor Kelly Kiejda
SchemeTravel Grant
RoleLead
Funding Start2011
Funding Finish2011
GNoG1100938
Type Of FundingInternal
CategoryINTE
UONY

20101 grants / $21,600

The identification of microRNA's as therapeutic targets for the treatment of advanced breast cancer$21,600

Funding body: Hunter Medical Research Institute

Funding bodyHunter Medical Research Institute
Project TeamDoctor Kelly Kiejda, Professor Rodney Scott, Professor John Forbes
SchemeResearch Grant
RoleLead
Funding Start2010
Funding Finish2010
GNoG0900144
Type Of FundingContract - Aust Non Government
Category3AFC
UONY

20094 grants / $387,000

Targeting p53 isoforms, delta-40p53 and p53-beta, to promote chemo-sensitivity in human melanoma$272,000

Funding body: Cancer Council NSW

Funding bodyCancer Council NSW
Project TeamProfessor Xu Dong Zhang, Conjoint Professor Peter Hersey, Doctor Kelly Kiejda
SchemeResearch Grant
RoleInvestigator
Funding Start2009
Funding Finish2009
GNoG0188913
Type Of FundingGrant - Aust Non Government
Category3AFG
UONY

Targeting p53 isoforms, delta-40p53 and p53-beta, to promote chemo-sensitivity in human melanoma$75,000

Funding body: Cancer Australia

Funding bodyCancer Australia
Project TeamDoctor Kelly Kiejda, Professor Xu Dong Zhang, Conjoint Professor Peter Hersey
SchemePriority-driven Collaborative Cancer Research Scheme
RoleLead
Funding Start2009
Funding Finish2009
GNoG0188914
Type Of FundingAust Competitive - Commonwealth
Category1CS
UONY

Targeting p53 isoforms in human melanoma$30,000

Funding body: Calvary Mater Newcastle

Funding bodyCalvary Mater Newcastle
Project Team
SchemeProject Grant
RoleLead
Funding Start2009
Funding Finish2009
GNo
Type Of FundingInternal
CategoryINTE
UONY

The microRNA signature of endoplasmic reticulum stress in melanoma$10,000

Funding body: Calvary Mater Newcastle

Funding bodyCalvary Mater Newcastle
Project Team
SchemeProject Grant
RoleInvestigator
Funding Start2009
Funding Finish2009
GNo
Type Of FundingInternal
CategoryINTE
UONY

20073 grants / $105,000

Characterization of p53 isoforms in human melanoma: do they play a role in chemoresistance?$75,000

Funding body: Cure Cancer Australia Foundation

Funding bodyCure Cancer Australia Foundation
Project Team
SchemeResearch Grant
RoleInvestigator
Funding Start2007
Funding Finish2007
GNo
Type Of FundingGrant - Aust Non Government
Category3AFG
UONY

The role of p53 Isoforms in chemoresistances of human melanoma$20,000

Funding body: Hunter Medical Research Institute

Funding bodyHunter Medical Research Institute
Project TeamProfessor Xu Dong Zhang, Doctor Kelly Kiejda
SchemeProject Grant
RoleInvestigator
Funding Start2007
Funding Finish2007
GNoG0187239
Type Of FundingContract - Aust Non Government
Category3AFC
UONY

The role of p53 isoforms in chemoresistance of human melanoma$10,000

Funding body: Calvary Mater Newcastle

Funding bodyCalvary Mater Newcastle
Project Team
SchemeProject Grant
RoleInvestigator
Funding Start2007
Funding Finish2007
GNo
Type Of FundingInternal
CategoryINTE
UONY

20061 grants / $332,000

Cameron Fellowship in Melanoma Research$332,000

Funding body: Melanoma and Skin Cancer Research Institute

Funding bodyMelanoma and Skin Cancer Research Institute
Project Team
Schemefellowship
RoleLead
Funding Start2006
Funding Finish2009
GNo
Type Of FundingInternal
CategoryINTE
UONY

20012 grants / $82,750

Australian Postgraduate Award$64,750

Scholarship support for PhD
Funding body: Department of Education, Training & Youth Affairs

Funding bodyDepartment of Education, Training & Youth Affairs
Project Team
SchemeScholarship support for PhD
RoleLead
Funding Start2001
Funding Finish2004
GNo
Type Of FundingAust Competitive - Commonwealth
Category1CS
UONY

Millennium Foundation Stipend Enhancement Grant$18,000

Funding body: Millennium Foundation

Funding bodyMillennium Foundation
Project Team
SchemeStipend enhancement grant
RoleLead
Funding Start2001
Funding Finish2004
GNo
Type Of FundingNot Known
CategoryUNKN
UONY
Edit

Research Supervision

Current Supervision

CommencedResearch Title / Program / Supervisor Type
2012p53 Isoforms in Breast Cancer
Health, Faculty of Health and Medicine
Principal Supervisor
2012The Functional Role of MicroRNAs Associated With Lymph Node Metastasis in Triple Negative Breast Cancer
Health, Faculty of Health and Medicine
Co-Supervisor
2010Role of Tandem Repeats in Genetic Susceptibility to Breast Cancer
Health, Faculty of Health and Medicine
Co-Supervisor

Past Supervision

YearResearch Title / Program / Supervisor Type
2014The Contribution of Genetic Susceptibility to Breast Cancer
Health, Faculty of Health and Medicine
Co-Supervisor
2011p53 isoforms in breast cancer
Medical Science, University of Newcastle
Principal Supervisor
Edit

Dr Kelly Kiejda

Position

Research Fellow
Information Based Medicine
School of Biomedical Sciences and Pharmacy
Faculty of Health and Medicine

Focus area

Medical Genetics

Contact Details

Emailkelly.kiejda@newcastle.edu.au
Phone4042 0309
Fax4042 0031

Office

RoomRm 3104, Lvl 3, West
BuildingHunter Medical Research Institute
LocationLot 1 Kookaburra Circuit, New Lambton Heights, NSW 2305

,
Edit